Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2002

View Archived Issues

IL-7, a potentially therapeutic cytokine for IPF

CVT-124 and furosemide preserve renal function and promote natriuresis in heart failure

Anticancer drug DTS-101 in late preclinical development

Genelabs and University of Iowa research the impact of hepatitis G on HIV infection

Zomig RM approved in Japan

Hemosol updates progress of Hemolink

Smallpox vaccine enters phase I trial

CP-248 shows potent activity against rat and human CNS cancer cell lines

Potential efficacy of the selective proteasome inhibitor PS-519 as a treatment for psoriasis

First live diagnostic test for mad cow and Creutzfeldt-Jakob disease

MorViva completes phase II study ahead of schedule

Neurocrine and Wyeth extend EAAT-3 collaboration

ACP-HIP approaches clinical testing

Go-ahead for phase II pilot study of CT-3 in chronic neuropathic pain

Avicine set to enter phase III in pancreatic cancer

TNX-901 increases symptom threshold to peanuts in phase II allergy study

Oxford GlycoSciences reports 36-month data from Vevesca study in Gaucher's disease

Initial stage completed in phase III trial of Tarceva in pancreatic cancer

Patient enrollment begins in pivotol Phase III Oncophage for melanoma study

Inex releases positive interim results for Onco TCS in small cell lung cancer trial

Novel peptides with calcium channel blocking activity reported by Suntory

Medinox designs a new class of modified NSAIDs with improved side effect profile

Japan Science and Technology patents new antibacterial compounds active against MRSA and VRE

New antibacterial compounds prepared by researchers at Kinki University

Japanese researchers identify new, potent and selective antifungal compounds

CancerVax puts hold on new patient enrollment in Canvaxin trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...